Adherence to Typical Antipsychotics among Patients with Schizophrenia in Uganda: A Cross-Sectional Study.

Autor: Kule M; Department of Psychiatry, Mbarara Regional Referral Hospital, Mbarara, Uganda., Kaggwa MM; Department of Psychiatry and Behavioural Neurosciences, McMaster University, Canada.; Department of Psychiatry, Mbarara University of Science and Technology, Uganda.
Jazyk: angličtina
Zdroj: Schizophrenia research and treatment [Schizophr Res Treatment] 2023 Feb 03; Vol. 2023, pp. 7035893. Date of Electronic Publication: 2023 Feb 03 (Print Publication: 2023).
DOI: 10.1155/2023/7035893
Abstrakt: Background: There has been a recent transition from typical to atypical antipsychotics in managing schizophrenia. This has been attributed to the acute side effects experienced by patients on typical antipsychotics that lead to nonadherence. However, the treatment cost with typical antipsychotics is cheaper (preferred in low-income settings), and there is no difference in the effectiveness, efficacy, discontinuation rate, or side effect symptom burden with atypical antipsychotics. This study is aimed at determining the prevalence of nonadherence and the associated factors to typical antipsychotics among patients with schizophrenia attending a psychiatric outpatient clinic at a rural tertiary facility in Uganda.
Method: A cross-sectional study among 135 patients with schizophrenia for at least six months on typical antipsychotics (mean age of 39.7 (±11.9) and 55.6% were female) from a rural tertiary facility in Uganda. Data were collected regarding sociodemographics, adherence, insight for psychosis, attitude towards typical antipsychotics, side effects, satisfaction with medications, and explanations from health workers about medications and side effects. Logistic regression was used to determine the factors associated with nonadherence.
Results: The prevalence of nonadherence was 16.3%, and the likelihood of being nonadherent was more among the poor (monthly earning below the poverty line). However, having reduced energy was associated with reducing the likelihood of having nonadherence.
Conclusion: The prevalence of nonadherence was lower than many previously obtained prevalence and was comparable to nonadherence for atypical antipsychotics. However, to reduce nonadherence, we need all stakeholders (such as the government, insurance companies, and caregivers) to assist patients living in poverty with access to medication.
Competing Interests: The authors declare that they have no competing interests.
(Copyright © 2023 Moses Kule and Mark Mohan Kaggwa.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje